What is Zacks Research’s Estimate for ESPR FY2025 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Esperion Therapeutics in a note issued to investors on Thursday, November 28th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn $0.06 per share for the year, down from their previous estimate of $0.09. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

Several other brokerages have also issued reports on ESPR. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC decreased their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $3.25 on Monday. Esperion Therapeutics has a one year low of $1.35 and a one year high of $3.44. The stock has a market cap of $640.38 million, a P/E ratio of -5.08 and a beta of 1.01. The company has a fifty day moving average price of $2.18 and a 200 day moving average price of $2.17.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently made changes to their positions in ESPR. Vanguard Group Inc. raised its holdings in Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the period. SG Americas Securities LLC grew its stake in Esperion Therapeutics by 45.3% in the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 11,658 shares during the period. Capital Advisors Wealth Management LLC increased its holdings in shares of Esperion Therapeutics by 22.9% in the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 5,000 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new stake in Esperion Therapeutics during the 2nd quarter worth approximately $132,000. Finally, Bank of New York Mellon Corp boosted its stake in Esperion Therapeutics by 3,278.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares during the period. 47.39% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.